Schlieren / Zurich, Switzerland, 19 August, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and ...

Paris-based Ipsen (IPSEY) to acquire Switzerland's Memo Therapeutics AG in a deal worth more than €700M (~$825M), expanding its rare disease portfolio with an experimental treatment for BK ...

Law360 (July 1, 2026, 4:06 PM EDT) -- French drugmaker Ipsen said Wednesday it has agreed to acquire Swiss biotechnology company Memo Therapeutics AG in a deal that could be worth more than €700 ...

Ipsen has outlaid €700m ($798.4m) to acquire rare disease specialist Memo Therapeutics – enriching its pipeline with a mid-stage clinical asset. As part of the takeover, the Paris, France-based pharma ...

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of ...

Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial ...

-- Strategic research collaboration to advance MTx's recombinant polyclonal IgG technology -- Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the ...

Complete SAFE KIDNEY II data confirm sustained reduction in viral load and resolution of biopsy-proven BKPyV-associated nephropathy with continued antiviral effect to 38 weeks Systematic literature ...

Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics AG and its phase III-ready drug potravitug, a treatment for BK ...